| Serial Number | 90461170 |
| Word Mark | ACUJJERA |
| Filing Date | Tuesday, January 12, 2021 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, May 23, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 24, 2021 |
| Goods and Services | Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); Pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medical reagents; Medical diagnostic reagents, assays, and test kits for testing of body fluids; Cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely, cancer, for medical use |
| Goods and Services | Medical services; Medical testing services; DNA screening and analysis services for medical purposes |
| Goods and Services | Pharmaceutical research and development; Development of pharmaceutical preparations and drugs; Development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers; Scientific research and development; Scientific laboratory services; Medical laboratory services; Conducting clinical trials for others; Conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers; DNA screening and analysis services for scientific research purposes |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 12, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 12, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 12, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Sierra Oncology, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Wilmington, DE 19808 |
| Party Name | Sierra Oncology, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Vancouver, B.C. V6C3E8 CA |
| Event Date | Event Description |
| Wednesday, October 19, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, October 19, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, October 19, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, October 12, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, October 12, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Wednesday, October 12, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, October 12, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, May 23, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, May 23, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, October 19, 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, August 24, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 24, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 4, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, July 22, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, July 22, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, July 22, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, July 22, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, July 22, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, July 21, 2021 | ASSIGNED TO EXAMINER |
| Tuesday, April 27, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, April 27, 2021 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Tuesday, April 27, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, April 27, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, April 12, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Friday, January 15, 2021 | NEW APPLICATION ENTERED IN TRAM |